Lacosamide UCB Europäische Union - Litauisch - EMA (European Medicines Agency)

lacosamide ucb

ucb pharma s.a. - lakozamidas - epilepsijos, dalinis - antiepileptics, - lacosamide ucb yra nurodyta kaip monotherapy ir adjunctive terapijos gydymo dalies pasireiškė traukuliai su ar be antrinės apibendrinimo suaugusiems, paaugliams ir vaikams nuo 4 metų amžiaus, su epilepsija.

Folotyn Europäische Union - Litauisch - EMA (European Medicines Agency)

folotyn

allos therapeutics ltd - pralatrexate - limfoma, t-ląstelė - antinavikiniai vaistai - gydymo periferinė t ląstelių limfoma,.

Zelnorm Europäische Union - Litauisch - EMA (European Medicines Agency)

zelnorm

novartis europharm limited - tegaserodas - dirgliosios žarnos sindromas - narkotikai funkciniams virškinimo trakto sutrikimams - zelnorm yra nurodyta pakartotinai simptominis trumpalaikis požiūris į moteris su dirgliosios Žarnos sindromas (ibs), kurių vyraujantis žarnyno įprotis yra vidurių užkietėjimas, susijęs su pilvo skausmas/diskomfortas ar pilvo pūtimas (žr. skyrių 4.

Veraflox Europäische Union - Litauisch - EMA (European Medicines Agency)

veraflox

bayer healthcare ag - pradofloksacinas - antibakteriniai preparatai sisteminiam naudojimui - Šunys - Šunys:, infekcija, odos ir minkštųjų audinių, i. paviršinių ir giliųjų pyoderma ir žaizdų infekcijų, kurias sukelia gram-teigiamų organizmų, paprastai staphylococcus spp. ir streptococcus spp. ir gram-neigiamų organizmų (pvz., escherichia coli, pseudomonas spp. ir proteus spp. , infekcijos, šlapimo takų sukelia gram-neigiamų bakterijų, pavyzdžiui, enterobacteriaceae, e. escherichia coli, enterobacter spp. , klebsiella spp. ir proteus spp. , pseudomonas spp. ir gram-teigiamų organizmų, paprastai staphylococcus spp. , infekcijų gingiva ir periodonto audinių sukelia anaerobinės organizmų, pavyzdžiui, porphyromonas spp. , prevotella spp. ; fusobacterium spp. , eikenella spp. ir capnophilic bakterijų, pavyzdžiui, capnocytophaga spp. , , cats:, infections of the respiratory tract caused by gram-negative organisms such as pasteurella spp. , escherichia coli ir pseudomonas spp. ir gram-teigiamų organizmų (pvz., streptococcus spp. ir staphylococcus spp.

Sarclisa Europäische Union - Litauisch - EMA (European Medicines Agency)

sarclisa

sanofi winthrop industrie - isatuximab - daugybinė mieloma - antinavikiniai vaistai - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Blenrep Europäische Union - Litauisch - EMA (European Medicines Agency)

blenrep

glaxosmithkline (ireland) limited - belantamab mafodotin - daugybinė mieloma - antinavikiniai vaistai - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Qutavina Europäische Union - Litauisch - EMA (European Medicines Agency)

qutavina

eurogenerics holdings b.v. - teriparatide - osteoporozė - kalcio homeostazė - qutavina is indicated in adults. osteoporozės po menopauzės moterims, ir vyrams, kuriems padidėjusi kaulų lūžių rizika. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. gydymo osteoporozės susijusi su ilgalaikis sisteminis gliukokortikoidų terapija moterims ir vyrams padidėjusi rizika lūžis.

Livogiva Europäische Union - Litauisch - EMA (European Medicines Agency)

livogiva

theramex ireland limited - teriparatide - osteoporozė - kalcio homeostazė - livogiva is indicated in adults. osteoporozės po menopauzės moterims, ir vyrams, kuriems padidėjusi kaulų lūžių rizika. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. gydymo osteoporozės susijusi su ilgalaikis sisteminis gliukokortikoidų terapija moterims ir vyrams padidėjusi rizika lūžis.

Nexpovio Europäische Union - Litauisch - EMA (European Medicines Agency)

nexpovio

stemline therapeutics b.v. - selinexor - daugybinė mieloma - antinavikiniai vaistai - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

CircoMax Myco Europäische Union - Litauisch - EMA (European Medicines Agency)

circomax myco

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - imunologiniai vaisiai suidae - kiaulių (mėsiniai) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.